Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234063 · ClinicalTrials.gov registry record · NA
Genetic Testing to Understand and Address Renal Disease Disparities
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 2,052
- Enrollment target
NCT02234063: Completed NA study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02234063 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 2,052 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234063, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,052 participants
- Enrollment target
Study Summary
In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension .
Primary Outcome
Number of participants with urine protein excretion in urine tests to assess kidney function at 12 months as compared to baseline
Interventions
- OTHER Immediate Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,052 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-01-12 |
| Phase | NA |
What the finished NCT02234063 record still lists
NCT02234063 is an interventional study that assigns participants to a tested intervention. Its 2,052 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 1 intervention - of which Immediate Genetic Testing is the first listed.
NCT02234063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02234063 about?
NCT02234063 is a clinical study titled "Genetic Testing to Understand and Address Renal Disease Disparities". In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic r...
What is the current status of trial NCT02234063?
This trial is currently completed. It is a NA study. The enrollment target is 2,052 participants. The study started on 2014-11. Estimated completion is 2018-01-12.
What interventions are being tested in trial NCT02234063?
The interventions under investigation include: Immediate Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT02234063?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02234063's enrollment target sits among peer trials
2,052 51st of 2000 higher than 1,950 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia